MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

The global race to treat neurodegenerative diseases has reached a new tempo as iRegene Therapeutics pushes its cell therapy pipeline into key clinical stages in the U.S. and China. Concurrently, the ...

This review examines how GLP-1 receptor agonists may influence neurodegenerative disease biology through metabolic, ...

HONOLULU — A novel “moderate-affinity iron chaperone” known as ATH434 (Alterity Therapeutics) may slow disease progression in patients with multiple system atrophy (MSA), new research suggested. The ...

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

Alterity Therapeutics has outlined three priorities for 2026 following the successful completion in 2025 of a Phase II trial of ... Read More The post Alterity gears up for Phase III MSA trial, ...

—In a new study, the extent of microstructural damage in patients with early relapsing-remitting multiple sclerosis (RRMS) was associated with worse disability and spinal cord atrophy at 5 years. Here ...

A cross-sectional, prospective study found that gray matter atrophy was more prevalent in patients with more severe progressive multiple sclerosis (MS) compared with those with less severe progressive ...